Loss of Heterozygosity Analysis of Chromosomes 9, 10 and 17 in Gliomas in Families

Christopher J. Watling, Donald J. van Meyel, David A. Ramsay, David R. Macdonald and J. Gregory Cairncross

ABSTRACT: Background: Studies of sporadic malignant gliomas have identified structural abnormalities in a number of chromosomal regions, especially losses of DNA on 9p, 10 and 17p. Purpose: We undertook the following molecular analysis in families with glioma to determine the frequency of chromosomal losses in these regions and to test the utility of microsatellite markers in demonstrating losses of heterozygosity. Methods: Genomic DNA was extracted from tumor tissue and venous blood from 20 patients with a family history of glioma. Dinucleotide repeat polymorphisms (microsatellites) were analyzed by polymerase chain reaction to assess loss of constitutional heterozygosity (LOH) on 9p, 10 and 17p. Three polymorphic markers on chromosome 9 (D9S104, D9S161, D9S165), one on chromosome 10 (D10S209), and two on 17p (D17S786, D17S796) were used. Autoradiographic films were analyzed for LOH after radioactively labelled polymerase chain reaction products were resolved on denaturing formamide-acrylamide gels. Results: Of 20 patients informative for at least one of three chromosome 9 markers, 12 (60%) showed LOH at one or more loci; of 9 informative for the chromosome 10 marker, 4 (44%) showed LOH; and of 16 informative for at least one of two chromosome 17 markers, 7 (44%) showed LOH at one or both loci. These LOH rates do not include instances of tumor nullizygosity (0 - 35%) and therefore represent minimum frequencies of chromosomal losses at these loci. Conclusions: Microsatellite markers can be used to detect LOH in archival glioma tissue. As in sporadic gliomas, frequent LOH was observed on 9p (9p21-22), 10 and 17p, supporting the notion that these regions may harbour tumor suppressor genes important in glioma development. Further work will be required to determine whether the proportion of LOH in these chromosomal regions is higher in familial gliomas than sporadic ones, as might occur with an inherited suppressor gene conferring susceptibility to gliomas in families.

Gliomas are the commonest primary brain tumors of adults. Most gliomas occur sporadically, but families with multiple affected members have been described.1 The study of such families may lead to the isolation of susceptibility genes which predispose to glioma development. "Familial" gliomas are uncommon, but in one recent study, 6.7% of patients with newly diagnosed glial tumors gave a family history of glioma. Dinucleotide repeat polymorphisms (microsatellites) were analyzed by polymerase chain reaction to assess loss of constitutional heterozygosity (LOH) on 9p, 10 and 17p. Three polymorphic markers on chromosome 9 (D9S104, D9S161, D9S165), one on chromosome 10 (D10S209), and two on 17p (D17S786, D17S796) were used. Autoradiographic films were analyzed for LOH after radioactively labelled polymerase chain reaction products were resolved on denaturing formamide-acrylamide gels. Results: Of 20 patients informative for at least one of three chromosome 9 markers, 12 (60%) showed LOH at one or more loci; of 9 informative for the chromosome 10 marker, 4 (44%) showed LOH; and of 16 informative for at least one of two chromosome 17 markers, 7 (44%) showed LOH at one or both loci. These LOH rates do not include instances of tumor nullizygosity (0 - 35%) and therefore represent minimum frequencies of chromosomal losses at these loci. Conclusions: Microsatellite markers can be used to detect LOH in archival glioma tissue. As in sporadic gliomas, frequent LOH was observed on 9p (9p21-22), 10 and 17p, supporting the notion that these regions may harbour tumor suppressor genes important in glioma development. Further work will be required to determine whether the proportion of LOH in these chromosomal regions is higher in familial gliomas than sporadic ones, as might occur with an inherited suppressor gene conferring susceptibility to gliomas in families.

positive and verifiable family history of glioma. An understanding of the genetic mechanisms underlying the development of these seemingly familial cases may prove equally relevant to sporadically occurring gliomas, since sporadic cancers generally arise as a result of the same genetic alterations which occur in their inherited counterparts. Most cancers, including glioma, occur as a result of a multistep process involving the accumulation of genetic mutations at critical loci, which cause activation of oncogenes and inactivation of tumor suppressor genes. While oncogenes are growth-promoting, tumor suppressor genes function to constrain cell growth and play a role in the normal processes of tissue differentiation and cell death. Loss of a normal tumor suppressor allele usually involves the loss of neighbouring chromosomal regions as well, so that the consistent observation in tumors of loss of heterozygosity (LOH) for a particular chromosomal marker implies the presence of a closely mapping tumor suppressor gene that is involved in the genesis of that tumor. LOH at non-random frequency has been consistently reported at a number of different loci in sporadic gliomas, especially 9p, 10p, 11p, and 17p, suggesting that the inactivation of multiple tumor suppressor genes located in these regions may play a role in glioma development. Of particular interest is region 9p21, the site of a putative tumor suppressor gene involved in the development of many cancers, including gliomas. Demonstration of LOH in gliomas has generally involved conventional Southern blotting and hybridization techniques. A newer method utilizing microsatellite markers and the polymerase chain reaction (PCR) is now available. Microsatellites are highly polymorphic simple sequence repeats distributed widely throughout the human genome. Their abundance, polymorphous nature, and amenability to PCR have made them extremely useful in genetic studies. The PCR-based technique offers the additional advantages of being faster and consuming less DNA than conventional blotting and hybridization. The goals of this study were to determine LOH frequencies in regions thought to harbour tumor suppressor genes relevant to gliomas, to ascertain whether certain losses were more common in “familial” than sporadic gliomas, and to test the applicability of microsatellite markers to this type of analysis.

MATERIALS AND METHODS

Patients and tissue samples

Twenty glioma patients (14 males, six females) with a family history of glioma and on whom both blood and tumor tissue were readily available were chosen for this study. These 20 patients were drawn from 17 families, 12 of which have been reported previously. Among these 17 families, the relationships between affected members were first degree in six, second degree in 10, and third degree in one. Our 20 study patients included three pairs of related individuals; the remaining 14 patients were unrelated probands. The tumor types included seven glioblastomas, three anaplastic astrocytomas, three mixed gliomas, three oligodendrogliomas, two astrocytomas, one ganglioglioma, and one primitive neuroglial tumor. In nine patients, tumor samples were obtained at the time of surgery and in eight of these the samples were frozen for periods of one to nine years prior to analysis. In the remaining 11 patients, archival paraffin-embedded tumor tissue from pathology specimens was used. For all 20 patients, peripheral venous blood was used as the source of normal genomic DNA.

DNA isolation

Frozen tumor samples were minced with a scalpel, suspended in digestion buffer (75 mM sodium chloride, 24 mM EDTA), and ground to a single-cell suspension using a manual homogenizer. Proteinase K (200 µg/ml) and sodium dodecyl sulphate (0.5%) were then added and the samples incubated overnight at 42°C on a rotator platform shaker. After treatment at 60°C for 1 hour, the samples were extracted once with an equal volume of phenol, once with a 50:50 mixture of phenol and chloroform, and once with chloroform. Ethanol precipitation of DNA was followed by resuspension in a 100 mM Tris-Cl (pH 7.5), 10 mM EDTA solution containing 50 µg/ml ribonuclease A. Samples were then incubated for 2 hours at 37°C, extracted with phenol and chloroform, and precipitated with ethanol. Paraffin-embedded samples were first treated with xylene then washed twice with ethanol prior to digestion with proteinase K as above.

Venous blood was centrifuged and the pellet incubated with 5 volumes of pre-warmed ammonium chloride (140 mM): Tris (17 mM) solution at 37°C for 15 minutes. Samples were centrifuged again and the pellets were rinsed twice with phosphate buffered saline then digested and treated as above with the exception of the ribonuclease treatment.

Polymerase chain reactions

The following microsatellite markers were used: D9S104, D9S161, and D9S165 on 9p21-22, D10S209 on 10q24-26, and D17S786 and D17S796 on 17p13.1 (Research Genetics, Huntsville, Alabama). The forward primer of each marker pair was end-labelled with [γ-32P] dATP using T4 polynucleotide kinase (Gibco BRL, Gaithersburg, Maryland). Each 25 µl polymerase chain reaction (PCR) contained up to 50 ng of DNA, 200 µmol of each deoxynucleotide triphosphate, 0.625 units of Taq polymerase, and 0.32 µmol of each primer in 1 mM magnesium chloride, 10 mM HEPES, and 50 mM potassium chloride. Less than 50 ng of DNA was used in 5 of the 20 normal samples and 5 of the 20 tumor samples because the amounts of DNA isolated were too small to permit the use of higher concentrations. Thermal cycling entailed an initial denaturation at 87°C for 7 minutes followed by 30 cycles of denaturation (92°C, 1 minute), annealing (50°C, 2 minutes) and extension (72°C, 1 minute), with a final 72°C extension for 7 minutes. When products of these reactions did not produce intense bands on autoradiography, reactions were repeated with the amount of DNA template tripled (up to 150 ng) to improve yield.

Electrophoresis and autoradiography

PCR products were denatured at 94°C for 3 minutes then resolved on formamide-acrylamide gels (8% acrylamide, 32% formamide, 5.6 M urea in 1X Tris borate EDTA buffer) as described by Litt et al. Gels were subjected to autoradiography with exposure times of 16 - 96 hours. Autoradiographs were examined visually for LOH. If necessary, scanning densitometry was used to confirm the result. Allelic loss was presumed when the ratio of the intensity of one of the tumor alleles to its corresponding normal allele was less than 50% of the ratio of the intensities of the other allele pair.

RESULTS

Results are summarized in the Table, with representative autoradiographs shown in the Figure. Samples whose PCR product for a
particular marker produced no bands when resolved electrophoretically were classified nullizygous.

**Chromosome 9**

Of 12 cases informative for marker D9S104, six (50%) showed LOH. Of the eight remaining cases, six were non-informative due to constitutional homozygosity and two showed heterozygosity for blood and nullizygosity for tumor DNA. Of 16 cases informative for marker D9S161, 10 (62.5%) showed LOH. All four remaining cases were non-informative due to constitutional homozygosity. Of 11 remaining cases, four were non-informative due to constitutional homozygosity, three showed heterozygosity for blood and nullizygosity for tumor DNA. Overall, 20 patients were informative for at least one of the two chromosome 9 markers examined and 12 (60%) showed LOH at one or more loci.

**Chromosome 10**

Of nine cases informative for marker D10S209, four (44%) showed LOH. Of the 11 remaining cases, four were non-informative due to constitutional homozygosity, four showed heterozygosity for blood and nullizygosity for tumor DNA, and three showed homoyzgosity for blood and nullizygosity for tumor DNA.

**Chromosome 17**

Of 12 cases informative for marker D17S786, four (33%) showed LOH. Of the eight remaining cases, two were non-informative due to constitutional homozygosity, five showed heterozygosity for blood and nullizygosity for tumor DNA, and one showed homoyzgosity for blood and nullizygosity for tumor DNA. Of 14 cases informative for marker D17S796, seven (50%) showed LOH. Of the six remaining cases, one was non-informative due to constitutional homozygosity, four showed heterozygosity for blood and nullizygosity for tumor DNA, and one showed homoyzgosity for blood and nullizygosity for tumor DNA. Overall, 16 patients were informative for at least one of the two chromosome 17 markers examined and seven (44%) showed LOH at one or both loci.

**DISCUSSION**

Substantial LOH rates were observed on chromosomes 9p, 10q, and 17p in "familial" gliomas, in keeping with the view that glioma development involves a series of genetic alterations occurring at multiple chromosomal loci. The highest LOH frequency was noted for the three chromosome 9 markers, all of which localize to 9p21-22.18,19 LOH in this region was observed in all tumor grades (five of seven glioblastomas, two of three anaplastic astrocytomas, two of two astrocytomas), suggesting that 9p21-22 loss may be an early event in tumor development, though the number of cases in each tumor grade is small. Previous studies have demonstrated frequent DNA losses at 9p22, a region containing the interferon gene cluster.17 Miyakoshi and colleagues reported genetic alterations in the IFNA-IFNB region in 10 of 19 malignant glioma cell lines,21 while James et al. showed that homozygous deletions in glioma cell lines on 9p were limited to a small region which includes most of the IFNA gene cluster.21 These data have led many to suggest that either the interferon class of genes themselves or another closely linked gene may function as a tumor suppressor whose inactivation is important in the progression of gliomas.5,6,20,22 More recent studies

---

**Table. Summary of microsatellite results and pathology of twenty familial gliomas.**

<table>
<thead>
<tr>
<th>Patient No. (sex/age at diagnosis,y)</th>
<th>Relationship</th>
<th>Pathology</th>
<th>Results of Microsatellite Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>D9S104</td>
</tr>
<tr>
<td>1(M/44)</td>
<td>2</td>
<td>GBM</td>
<td>HR</td>
</tr>
<tr>
<td>2(F/47)</td>
<td>1</td>
<td>GBM</td>
<td>-</td>
</tr>
<tr>
<td>3(M/57)</td>
<td>2</td>
<td>GBM</td>
<td>-</td>
</tr>
<tr>
<td>4(M/55)</td>
<td>2</td>
<td>GBM</td>
<td>-</td>
</tr>
<tr>
<td>5(M/68)</td>
<td>2</td>
<td>GBM</td>
<td>-</td>
</tr>
<tr>
<td>6(M/51)</td>
<td>2</td>
<td>GBM</td>
<td>N/HT</td>
</tr>
<tr>
<td>7(M/54)</td>
<td>1</td>
<td>GBM</td>
<td>LOH</td>
</tr>
<tr>
<td>8(F/28)</td>
<td>2</td>
<td>AA</td>
<td>LOH</td>
</tr>
<tr>
<td>9(F/28)</td>
<td>3</td>
<td>AA</td>
<td>HR</td>
</tr>
<tr>
<td>10(M/23)</td>
<td>1</td>
<td>AA</td>
<td>HR</td>
</tr>
<tr>
<td>11(M/56)</td>
<td>2</td>
<td>OA</td>
<td>HR</td>
</tr>
<tr>
<td>12(M/17)</td>
<td>3</td>
<td>OA</td>
<td>HR</td>
</tr>
<tr>
<td>13(M/38)</td>
<td>2</td>
<td>OA</td>
<td>LOH</td>
</tr>
<tr>
<td>14(M/40)</td>
<td>1</td>
<td>A</td>
<td>-</td>
</tr>
<tr>
<td>15(M/60)</td>
<td>2</td>
<td>A</td>
<td>LOH</td>
</tr>
<tr>
<td>16(M/36)</td>
<td>3</td>
<td>O</td>
<td>HR</td>
</tr>
<tr>
<td>17(F/25)</td>
<td>2</td>
<td>O</td>
<td>LOH</td>
</tr>
<tr>
<td>18(F/38)</td>
<td>1</td>
<td>O</td>
<td>LOH</td>
</tr>
<tr>
<td>19(M/46)</td>
<td>1</td>
<td>GG</td>
<td>N/HT</td>
</tr>
<tr>
<td>20(F/24)</td>
<td>2</td>
<td>PNGT</td>
<td>-</td>
</tr>
</tbody>
</table>

aDegree of relationship between study patient and closest glioma-affected relative. 1 = first degree, 2 = second degree, etc.

bGBM = glioblastoma, AA = anaplastic astrocytoma, OA = oligoastrocytoma, A = astrocytoma, O = oligodendrogliona, GG = ganglioglioma, PNGT = primitive neural tube.

LOH = loss of heterozygosity, HR = heterozygosity retained, N/HT = nullizygous tumor from heterozygous patient, N/HM = nullizygous tumor from homozygous patient, - = non informative.
of cell lines derived from multiple types of human cancer, including glioma, have shown frequent deletions of a region of 9p21 which contains a gene encoding an inhibitor (p16) of cyclin-dependent kinase 4, an enzyme that normally stimulates cell division.14,23 These data suggest that p16 may be an important tumor suppressor, though deletions of the p16 gene remain to be demonstrated in primary tumor samples. Our 60% LOH frequency at 9p21-22 supports the notion that a tumor suppressor gene is contained in this area and provides further justification for a more detailed study of this region.

LOH for loci on chromosome 10 has generally been associated with glioblastoma pathology, not with astrocytic gliomas of lower grade.18 In our study, LOH was observed in higher grade gliomas only (one of two informative glioblastomas, with three others showing nullizygosity, and two of two informative anaplastic astrocytomas), and not in low grade astrocytomas. Pershouse et al. introduced a copy of chromosome 10 into a human glioma cell line and demonstrated suppression of the tumorigenic phenotype in the hybrid clones in vitro and in vivo, suggesting that chromosome 10 also contains a tumor suppressor gene whose inactivation is required for glioma progression.24

LOH for loci on 17p is a frequent observation in glial tumors of all histologic grades, suggesting the presence of a tumor suppressor gene whose inactivation is an early event in glioma development.9-13 Consistent with this hypothesis, we found LOH at this locus in all tumor grades (one of seven glioblastomas, with three others showing nullizygosity for one or both markers, three of three anaplastic astrocytomas, and one of two astrocytomas). The two microsatellite markers on chromosome 17 used in this analysis map near 17p13.1.18 This the site of the tumor suppressor gene p53 whose inactivation appears to be an important step in the oncogenesis of many human tumors, including glioma. In some tumors, deletion of one copy of the p53 gene is accompanied by mutations in the remaining allele which render the gene product inactive.11,25

One of the challenges we encountered interpreting these data was the frequent occurrence of tumor nullizygosity - 10% for D9S104, 25% for D9S165, 35% for D10S209, 30% for D17S786, and 25% for D17S796. In all, nine tumors showed nullizygosity for at least one of the six loci examined. Of these nine tumors, DNA had been extracted from archival paraffin-embedded tissue in seven and from previously frozen gross tumor specimens in two. Because the yield of DNA was often low from small archival samples, it is possible that nullizygosity represents a technical problem due to low DNA concentration in the PCR mixture, and hence the failure of these DNA samples to amplify at these loci. However, none of the seven DNA samples derived from archival tissue was nullizygous for all six loci and the two DNA samples extracted from gross tumor specimens, where recovery of DNA was substantial, also demonstrated nullizygosity at one or more loci. These findings suggest that tumor nullizygosity may in at least some instances represent a true and important finding rather than a technical artifact. Some of these gliomas may have deletions of both alleles at these loci; such homozygous deletions have been described.5,6,21 Interestingly, six of the nine tumors showing nullizygosity were high grade anaplastic astrocytomas or glioblastomas, suggesting a relationship between malignant tumor pathology and more extensive deletions. The LOH frequencies reported here do not take instances of tumor nullizygosity into account, and therefore may underestimate the true frequency of genetic alterations in these tumors at these loci.

Certain individuals may be genetically predisposed to glioma, inheriting mutations in one or more of the genes responsible for glioma development. The finding of a significantly higher LOH rate for a particular chromosomal region in "familial" gliomas, or similar LOH patterns among related individuals, would support the notion of inherited susceptibility to glioma. The frequencies of LOH reported here are similar to those in previous studies of sporadic gliomas,5,13 though the use of microsatellite markers rather than restriction fragment length polymorphisms makes direct comparisons difficult. In most of our cases, only the proband of an affected family was treated at this centre, and opportunities to study tumor samples from related individuals have been limited thus far. Among the three pairs of related individuals in this study were one pair of second degree relatives (patients 6 and 17) and two pairs of third degree relatives (patients 5 and 16, patients 12 and 15). For each related pair, there were two markers for which both individuals were informative (excluding instances of nullizygosity), and in two of the three pairs the LOH patterns were the same for these two markers while in the third pair the pattern was the same for only one of the two markers. Any conclusion for or against a genetic basis for gliomas in families is premature given these limited data, but our results certainly support the need for further study of related affected individuals.
Finally, this study has demonstrated the usefulness of microsatellite markers in LOH analysis. Their amenability to PCR amplification makes it possible to undertake molecular analysis even when only small amounts of DNA are available, so that this technique can be applied to both fresh and archival tissue. As more of these highly polymorphic markers are accurately mapped, they will become increasingly valuable in determining the locations of genes involved in the development of gliomas and other cancers.

REFERENCES